Compare DLHC & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLHC | STRO |
|---|---|---|
| Founded | 1969 | 2003 |
| Country | United States | United States |
| Employees | 2300 | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 85.0M |
| IPO Year | 2012 | N/A |
| Metric | DLHC | STRO |
|---|---|---|
| Price | $6.23 | $21.69 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 7.8K | ★ 125.2K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,923,000.00 | N/A |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | $0.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.57 | N/A |
| 52 Week Low | $2.72 | $0.52 |
| 52 Week High | $8.09 | $27.96 |
| Indicator | DLHC | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 58.75 | 55.75 |
| Support Level | $5.56 | $0.76 |
| Resistance Level | $6.88 | $27.96 |
| Average True Range (ATR) | 0.25 | 2.20 |
| MACD | 0.02 | -0.30 |
| Stochastic Oscillator | 100.00 | 35.97 |
DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.